SCHEMBL593871

SCHEMBL593871

CNC1=NC(=O)N(c2cccc(F)c2)C12CCN(Cc1ccccc1)CC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.53
CYP2D6 P10635 5/20 0.46
MAPK1 P28482 1/20 0.46
BACE2 Q9Y5Z0 1/20 0.44
OPRL1 P41146 3/20 0.43
OPRM1 P35372 3/20 0.43
OPRD1 P41143 2/20 0.43
OPRK1 P41145 2/20 0.43
DOCK5 Q9H7D0 1/20 0.43
TSHR P16473 1/20 0.41
SIGMAR1 Q99720 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
HPGD P15428 1/20 0.40
KCNH2 Q12809 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
CACNA1F O60840 1/20 0.39
CHRM2 P08172 1/20 0.39
ADRB1 P08588 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8268324 0.89 BACE1 (0.53) BACE1CYP2D6MAPK1BACE2OPRL1
SCHEMBL593631 0.88 BACE1 (0.61) BACE1CYP2D6MAPK1BACE2DOCK5
SCHEMBL594162 0.87 BACE1 (0.51) BACE1CYP2D6MAPK1BACE2OPRL1
SCHEMBL592530 0.87 BACE1 (0.60) BACE1CYP2D6MAPK1BACE2OPRM1
SCHEMBL594163 0.87 BACE1 (0.49) BACE1CYP2D6MAPK1BACE2OPRL1
SCHEMBL593161 0.85 BACE1 (0.59) BACE1CYP2D6MAPK1BACE2OPRL1
SCHEMBL8269122 0.84 BACE1 (0.48) BACE1CYP2D6MAPK1BACE2OPRL1
SCHEMBL594592 0.82 CYP3A4 (0.41) CYP2D6MAPK1TSHRCYP1A2CYP3A4
SCHEMBL593724 0.82 BACE1 (0.44) BACE1CYP2D6MAPK1BACE2OPRM1
SCHEMBL15146181 0.81 BACE1 (0.44) BACE1CYP2D6MAPK1BACE2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8114887-B2 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp. (US) 2012-02-14 US claimed
EP-1804794-B1 SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER S DISEASE MERCK SHARP & DOHME (US) 2013-07-31 EP disclosed
EP-1804794-B1 SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER S DISEASE MERCK SHARP & DOHME (US) 2013-07-31 EP disclosed
US-8114887-B2 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp. (US) 2012-02-14 US disclosed
US-8114887-B2 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp. (US) 2012-02-14 US disclosed
US-8114887-B2 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp. (US) 2012-02-14 US disclosed
US-20070197571-A1 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease MERCK SHARP & DOHME LLC 2007-08-23 US disclosed
US-20070197571-A1 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease MERCK SHARP & DOHME LLC 2007-08-23 US disclosed
US-20070197571-A1 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease MERCK SHARP & DOHME LLC 2007-08-23 US disclosed
WO-2006044497-A2 SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER’S DISEASE MERCK & CO., INC. (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197571-A1 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease BACE1, BACE2, APP BACE1 1/4885CYP2D6 1339/4885MAPK1 2630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.